We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Headquartered in Greenwood Village, CO, Envision Healthcare Corporation , a provider of physician-led outsourced medical services to consumers, hospitals and healthcare systems in the U.S., recently announced the acquisition of Desert Mountain Consultants in Anesthesia, Inc. The acquired company’s 14 physicians provide anesthesia services at HonorHealth’s John C. Lincoln Medical Center and Deer Valley Medical Center, as well as at several ambulatory surgery centers.
We note that Envision Healthcare returned almost 6.8% in the last one month, slightly higher than the Zacks categorized Home Care Market sub-industry’s gain of roughly 6.7% and the S&P 500’s return of 5.0%.
Envision Healthcare recently announced the completion of its merger deal with physician and ambulatory services provider, AmSurg Corp. Notably, the merger has been sealed at a fixed exchange ratio of 0.334 AmSurg shares for each Envision share. Furthermore, the company has a long-term expected growth rate of 13.3%.
Meanwhile, the estimate revision trend seems quite favorable for the stock, with one estimate moving up in the past month. Notably, the current year estimate for the stock inched up by a penny to $4.02 per share over the past month.
Our Take
After the completion of the AmSurg deal, Envision Healthcare enterted into the S&P 500 stock index, a significant development in our view.
The latest development also holds considerable promise taking the global neonatal markets under consideration. Per a report by the Markets And Markets, the global fetal and neonatal care market is expected to reach a worth of $8.61 billion by 2020, multiplying at a CAGR of 6.5%.
Zacks Rank & Key Picks
Currently, Envision Healthcare has a Zacks Rank #3 (Hold).
Sucampo’s earnings estimates increased from $1.03 to $1.22 for 2016 and from $1.30 to $1.69 for 2017 over the last 60 days. The company posted a positive surprise in all of the four trailing quarters with an average beat of 35.55%.
Vanda’s loss estimates narrowed from 62 cents to 52 cents for 2016, while its earnings estimates increased from 13 cents to 22 cents for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 56.65%. Its share price has surged almost 73% year to date.
MannKind’s estimates narrowed from loss of 24 cents to earnings of 12 cents for 2016 over the last 60 days. For 2017, loss estimates narrowed from 14 cents to 9 cents over this period. The company posted a positive surprise in two of the four trailing quarters with an average beat of 103.33%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Envision Healthcare Acquires Desert Mountain Consultants
Headquartered in Greenwood Village, CO, Envision Healthcare Corporation , a provider of physician-led outsourced medical services to consumers, hospitals and healthcare systems in the U.S., recently announced the acquisition of Desert Mountain Consultants in Anesthesia, Inc. The acquired company’s 14 physicians provide anesthesia services at HonorHealth’s John C. Lincoln Medical Center and Deer Valley Medical Center, as well as at several ambulatory surgery centers.
We note that Envision Healthcare returned almost 6.8% in the last one month, slightly higher than the Zacks categorized Home Care Market sub-industry’s gain of roughly 6.7% and the S&P 500’s return of 5.0%.
Envision Healthcare recently announced the completion of its merger deal with physician and ambulatory services provider, AmSurg Corp. Notably, the merger has been sealed at a fixed exchange ratio of 0.334 AmSurg shares for each Envision share. Furthermore, the company has a long-term expected growth rate of 13.3%.
Meanwhile, the estimate revision trend seems quite favorable for the stock, with one estimate moving up in the past month. Notably, the current year estimate for the stock inched up by a penny to $4.02 per share over the past month.
Our Take
After the completion of the AmSurg deal, Envision Healthcare enterted into the S&P 500 stock index, a significant development in our view.
The latest development also holds considerable promise taking the global neonatal markets under consideration. Per a report by the Markets And Markets, the global fetal and neonatal care market is expected to reach a worth of $8.61 billion by 2020, multiplying at a CAGR of 6.5%.
Zacks Rank & Key Picks
Currently, Envision Healthcare has a Zacks Rank #3 (Hold).
Better-ranked stocks in the broader medical sector include MannKind Corporation (MNKD - Free Report) , Sucampo Pharmaceuticals, Inc. and Vanda Pharmaceuticals, Inc. (VNDA - Free Report) . All the three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Sucampo’s earnings estimates increased from $1.03 to $1.22 for 2016 and from $1.30 to $1.69 for 2017 over the last 60 days. The company posted a positive surprise in all of the four trailing quarters with an average beat of 35.55%.
Vanda’s loss estimates narrowed from 62 cents to 52 cents for 2016, while its earnings estimates increased from 13 cents to 22 cents for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 56.65%. Its share price has surged almost 73% year to date.
MannKind’s estimates narrowed from loss of 24 cents to earnings of 12 cents for 2016 over the last 60 days. For 2017, loss estimates narrowed from 14 cents to 9 cents over this period. The company posted a positive surprise in two of the four trailing quarters with an average beat of 103.33%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>